WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H329109
CAS#: 28319-77-9
Description: Choline Alfoscerate, also known as Alpha GPC and L-Alpha glycerylphosphorylcholine, is a component of PHOSPHATIDYLCHOLINES or LECITHINS, in which the two hydroxy groups of GLYCEROL are esterified with fatty acids. Choline Alfoscerate is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. Choline Alfoscerate is used in the treatment of Alzheimer's Disease and other dementias.
Hodoodo Cat#: H329109
Name: Choline Alfoscerate
CAS#: 28319-77-9
Chemical Formula: C8H20NO6P
Exact Mass: 257.10
Molecular Weight: 257.223
Elemental Analysis: C, 37.36; H, 7.84; N, 5.45; O, 37.32; P, 12.04
Synonym: Choline Alfoscerate; Alpha GPC; L-Alpha glycerylphosphorylcholine; Choline glycerophosphate
IUPAC/Chemical Name: (R)-2,3-dihydroxypropyl (2-(trimethylammonio)ethyl) phosphate
InChi Key: InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
InChi Code: InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
SMILES Code: OC[C@@H](O)COP(OCC[N+](C)(C)C)([O-])=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 257.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ricci A, Bronzetti E, Vega JA, Amenta F. Oral choline alfoscerate counteracts age-dependent loss of mossy fibres in the rat hippocampus. Mech Ageing Dev. 1992;66(1):81-91. PubMed PMID: 1340517.
2: Amenta F, Ferrante F, Vega JA, Zaccheo D. Long term choline alfoscerate treatment counters age-dependent microanatomical changes in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):915-24. PubMed PMID: 7972861.
3: Kostenko EV, Petrova LV, Artemova IIu, Vdovichenko TV, Ganzhula PA, Ismailov AM, Lisenker LN, Petrov SV, Otcheskaia OV, Rotor LD, Khozova AA, Boĭko AN. [The use of cerepro (choline alfoscerate) in the treatment of outpatients with chronic progressive cerebrovascular disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(3 Pt 1):24-30. Russian. PubMed PMID: 22677751.
4: Amenta F, Del Valle M, Vega JA, Zaccheo D. Age-related structural changes in the rat cerebellar cortex: effect of choline alfoscerate treatment. Mech Ageing Dev. 1991 Dec 2;61(2):173-86. PubMed PMID: 1824122.
5: Ciriaco E, Bronzetti E, Caporali MG, Germana' GP, Niglio T, Piccolo G, Ricci A, Scotti De Carolis A, Amenta F. Effect of choline alfoscerate treatment on changes in rat hippocampus mossy fibres induced by monolateral lesioning of the nucleus basalis magnocellularis. Arch Gerontol Geriatr. 1992 May-Jun;14(3):203-13. PubMed PMID: 15374385.
6: De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003 Jan;25(1):178-93. PubMed PMID: 12637119.
7: Bronzetti E, Felici L, Zaccheo D, Amenta F. Age-related anatomical changes in the rat hippocampus: retardation by choline alfoscerate treatment. Arch Gerontol Geriatr. 1991 Sep-Oct;13(2):167-78. PubMed PMID: 15374427.
8: Vega JA, Cavallotti C, del Valle ME, Mancini M, Amenta F. Nerve growth factor receptor immunoreactivity in the cerebellar cortex of aged rats: effect of choline alfoscerate treatment. Mech Ageing Dev. 1993 Jun;69(1-2):119-27. PubMed PMID: 8377526.
9: Kamilov KhM, Kasimova MS, Makhkamova DK. [Analysis of choline alfoscerate effectiveness in chronic ocular ischemic syndrome]. Vestn Oftalmol. 2016 Mar-Apr;132(2):73-6. Russian. PubMed PMID: 27213801.
10: Ilcol YO, Ozbek R, Hamurtekin E, Ulus IH. Choline status in newborns, infants, children, breast-feeding women, breast-fed infants and human breast milk. J Nutr Biochem. 2005 Aug;16(8):489-99. PubMed PMID: 16043031.
11: Holmes-McNary MQ, Cheng WL, Mar MH, Fussell S, Zeisel SH. Choline and choline esters in human and rat milk and in infant formulas. Am J Clin Nutr. 1996 Oct;64(4):572-6. PubMed PMID: 8839502.
12: Vinogradov OI, Daminov VD, Rybalko NV. [The use of choline alfoscerate (gliatiline) in patients with ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(1):43-5. Russian. PubMed PMID: 23528493.
13: Vaizova OE, Zautner NA, Alifirova VM, Vengerovskiĭ AI. [Influence of neuroprotectors with choline-positive action on the level of brain-injury markers during acute ischemic stroke]. Eksp Klin Farmakol. 2012;75(3):7-9. Russian. PubMed PMID: 22679745.
14: Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9. Review. PubMed PMID: 24156263.
15: Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clin Chem Lab Med. 2013 Mar 1;51(3):513-21. doi: 10.1515/cclm-2012-0559. Review. PubMed PMID: 23314552.
